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4LETTER TO THE EDITOR
ulmonary Cytolytic Thrombi after Allogeneic
ematopoietic Cell Transplantation: A Further
istologic Description
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bPulmonary cytolytic thrombi (PCT) is a recently
escribed complication of allogeneic hematopoietic
ell transplantation [1-3]. PCT presents with fever,
ough, chest pain, respiratory distress, and peripheral
odules on chest computed tomography [1]. Histolog-
cally, PCT appears as thrombi in the small to me-
ium distal pulmonary vessels with entrapped leuko-
ytes. There is associated endothelial disruption and
nfarction of adjacent lung tissue [2]. In our previous
eports [1,2,4], the pathologic specimens were not
ufﬁciently preserved to allow characterization of the
ntrapped leukocytes. Characterization of these cells
ay lead to an improved understanding of PCT.
A 5-year-old boy with precursor B-cell acute lym-
hoblastic leukemia in third complete remission re-
eived a 5/6 HLA antigen–matched, sex-mismatched
nrelated cord blood transplant. His initial posttrans-
lantation course was unremarkable, and day 21
tudies revealed 100% donor engraftment (Table 1).
ixed donor-recipient chimerism was detected at day
60, and the patient’s immunosuppression was rap-
dly tapered. At 70 days after transplantation, he de-
eloped a rash diagnosed as grade II skin graft-versus-
ost disease (GVHD). On day 81, the patient was
ospitalized with a low-grade fever and nonproductive
ough. A computed tomographic scan revealed diffuse
ulmonary interstitial opacities. The patient became
ersistently febrile and had a worsening respiratory
tatus despite broad-spectrum antibiotics and antifun-
al agents. Bronchoscopy was negative twice. Thora-
oscopic lung biopsy results on day 106 were con-
able 1. Percentage of Residual Recipient Cells versus Day after Alloge
21 60 77
ource of specimen BM PB PB
Residual host cells
M 0 8 7.2
N 0 15.5 12.8
ngraftment status was determined on samples from peripheral bloo
tissue using ﬂuorescence in situ hybridization.
indicates mononuclear cell fraction; N, neutrophil fraction; NA, not ap
84istent with PCT (Figure 1A). The histology of the
ung biopsy sample was well preserved, thus allowing
mmunohistochemical studies to be performed [2].
he basophilic cytolytic thrombi were composed en-
irely of leukocytes that stained positive for CD45,
D68, and myeloperoxidase, consistent with mono-
ytes (Figure 1B-D). The cells were negative for CD3,
D10, CD20, CD31, and CD1a (not shown). Special
tains for bacteria, fungi, and acid-fast organisms had
egative results (not shown). Culture of the tissue did
ot detect bacterial, viral, or fungal pathogens.
Little is known about the pathophysiology of
CT. Our previous attempts to characterize the cel-
ular component of PCT have been limited by poorly
reserved architecture of pathologic specimens and
ecrosis of the entrapped cells. Here we show that the
ells that make up PCT are exclusively monocytes. At
he time of lung biopsy, residual recipient cells were
etected in the peripheral blood (PB, day102; Table
). Because the recipient was male and the donor was
emale, we performed ﬂuorescence in situ hybridiza-
ion by using probes to the centromere regions of
hromosomes X and Y to determine the donor versus
ecipient origin of the monocytes in the PCT lesion.
luorescence in situ hybridization showed that 11% of
he cells within the thrombi were recipient (male;
igure 1E) at day 106, whereas only 3% of the cells
n the PB were recipient at a similar time (day 102;
able 1). One possible explanation for this observa-
ion is sampling discrepancy, although this is unlikely
ecause 400 single cells were counted by 2 cytoge-
matopoietic Stem Cell Transplantation
ay after Transplantation
102 103 106 131 140
PB BM PCT PB BM
2.7 0 11 0 0
4.5 0 NA 0 0
or bone marrow (BM) by using short tandem repeats and on PCTneic He
D
83
PB
5.6
9.1
d (PB)plicable.
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Pulmonary Cytolytic Thrombi after Allogeneic HCT
Beticists. Thus, the increased percentage of recipient
ells in the PCT lesion may reﬂect the engraftment
tatus of the patient when PCT developed. The per-
entage of recipient cells in the PB was closest to 11%
igure 1. Histologic evaluation of cytolytic thrombi. A, Pulmonary
ytolytic thrombus. The thrombus consists predominantly of cells with
onocytoid features; the muscular wall of the artery can be seen on top
stain, hematoxylin and eosin; original magniﬁcation,600). B, Strong
embrane reactivity for common leukocyte antigen. A negatively
tained arterial wall is seen at the right (immunoperoxidase stain for
D45; original magniﬁcation,600). C, Intense cytoplasmic reactivity
or the monocyte-macrophage marker CD68. A negatively stained
rterial wall is seen at the bottom right (immunoperoxidase stain;
riginal magniﬁcation, 600). D, Intense cytoplasmic reactivity for
yeloperoxidase is seen in cells of the cytolytic thrombus. A negatively
tained arterial wall is seen at the left (immunoperoxidase stain; original
agniﬁcation, 600). E, Fluorescence in situ hybridization analysis
howing 2 cells of female origin (2 green centromere X signals) and 1
ale cell (1 green centromere X signal and 1 red centromere Y signal).n day 60 (Table 1), approximately 3 weeks before
B&MThe onset of PCT symptoms, concurrent with the
mmune suppression taper and 10 days before the
nset of GVHD. Taken together, these results
emonstrate that the cells that make up the PCT
esion are monocytes and that these cells can be of
oth donor and recipient origin. Because a signiﬁ-
ant percentage of patients with PCT have GVHD
80%), concurrent infections (46%) [1], or both,
CT may represent monocyte recruitment to a pre-
iously injured lung.
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